Merck Millipore kicks off ‘EMPROVE Seminar Series’

Mumbai: Merck Millipore India launched  the ‘EMPROVE Seminar Series' at Taj Lands End, Mumbai. EMPROVE is a proprietary service from Merck Millipore which combines product quality with user-related documentation simplifying rigorous regulatory work for the pharmaceutical industry. The inaugural seminar on ‘Evolving Trends in Regulations in the US and EU' consisted of a panel of eminent speakers of international repute.

Panelists who addressed key issues in regulations included Mr Ajit Singh, chairman, ACG Worldwide, who spoke on the ‘Current Trends in the Pharmaceutical Industry with respect to Indian and International Regulations'. Also, Dr Bernd Renger, chairman, European Qualified Persons Association, addressed the seminar on ‘Challenges for Regulatory Compliance for the EU'.

Introducing the seminar Mr Peter Salazar, head, Pharm-Chem Solutions, Merck Millipore India, said that, "The regulatory landscape is changing and it is imperative for our industry to understand, interpret and prepare to meet the challenges of tomorrow. The EMPROVE Seminar Series is an endeavour by Merck Millipore to give back to the industry by bringing together under one roof experts from different fields to predict and better prepare for the future. With EMPROVE, we have established ourselves as leaders in quality and international regulatory compliance."

The EMPROVE seminar also saw reputed individuals like Mr Chandrashekar Deo, consultant, quality and GMP, who provided an overview of ‘The Changing Environment for Regulatory Compliance in the US'; Mr P Manoj Kumar, AVP, R&D, Mylan Laboratories, who spoke on ‘Developing Complex Parenteral Dosage Forms - A Generic Perspective'; Dr Sandeep Tiwari, regional technical manager, South Asia, Colorcon Asia, who spoke at length on ‘Examining the Impact of Excipient Variability on QbD', and Dr Ulrich Reichert, head, regulatory experts and customer audits, Merck Millipore, who gave insights into ‘Elemental Impurities - Perspective as per ICH/EU/US'.